. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
tight supply from shutdown of some Natural Fatty Alcohols producers in China and India in avoidance of risk during volatile crude palm kernel oil price. With this opportunity, the company ramped up our
broken into five sections: The Quality and Integrity of the Credit Rating Process; CRA Independence and the Avoidance of Conflicts of Interest; CRA Responsibilities to the Investing Public, Rated Entities
baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
circumstances in which the CRA operates. Structurally, the IOSCO CRA Code is broken into five sections: The Quality and Integrity of the Credit Rating Process; CRA Independence and the Avoidance of Conflicts of
avoidance of the provisions or the rules issued under the Law on Securities and Exchange; (2) the management of the mutual fund may contravene a public policy or government policy relating to the capital